What Bone Solutions does

Bone Solutions, Inc. is a privately held U.S. medical device company headquartered in Colleyville, Texas, that develops and commercializes magnesium-based orthopedic bone substitute products. The company's platform is built on a proprietary magnesium phosphate chemistry—formed from an acid/base crystallization reaction of magnesium oxide and phosphates—that is fully synthetic, fully resorbable, and remodels into native bone through creeping substitution. Its two commercial products are Mg OSTEOCRETE (a moldable/putty bone substitute available in high and medium viscosity formulations) and Mg OSTEOINJECT (a low-viscosity injectable formulation), each sold as kits in 5cc, 10cc, and 15cc sizes alongside separately sold accessories such as cannulas, mixing syringes, and bead mats. Products are FDA-registered and indicated for trauma, extremity, revision, sports medicine, and—in the case of Mg OSTEOCRETE—spine fusion applications.

The technology is differentiated by rapid set times (ready to implant in 30 seconds, fully set in 2 minutes for immediate drilling), superior adhesive/cohesive properties versus calcium phosphate cements, radiopacity that allows monitoring of remodeling progress, and a degradation rate tuned to provide structural support before resorbing as bone forms. Quantified preclinical outcomes include up to 43% greater screw removal force, up to 58% greater extraction torque, 50% better anchor fixation at 15 minutes, and nearly 4x more complete remodeling at 12 weeks compared with competitive bone substitutes.

Bone Solutions generates revenue through direct hardware sales of its medical device kits via a network of independent medical sales distributors who call on hospitals and surgical centers in the United States; the company is actively recruiting additional distributors. Its go-to-market emphasizes presence at major orthopedic and trauma conferences (AAOS, OTA, AAHKS, among others), a LinkedIn presence, and surgeon-testimonial-driven marketing. The company has raised approximately $1.92M across two disclosed funding rounds in 2015 and 2016, operates with 1-10 employees, has no disclosed international footprint, and has not publicly disclosed revenue.

Name

Bone Solutions

Legal name

Bone Solutions, Inc.

Website

https://bonesolutions.net

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

Bone Solutions is a U.S. medical device company that develops and sells magnesium phosphate bone substitute products (Mg OSTEOCRETE and Mg OSTEOINJECT) to orthopedic surgeons for trauma, revision, sports medicine, and spine procedures via independent medical sales distributors.

Ownership category

akta.pro rank

Product category

Orthopedic Bone Substitutes

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industry

Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)

Keywords

• Orthopedic bone substitutes
• Magnesium-based implants
• Bone graft materials
• Orthopedic medical devices
• Synthetic biologics

Headquarters

HQ city

Colleyville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Product Sales: Bone Solutions generates revenue through the sale of its magnesium-based bone substitute products sold as kits in multiple sizes (5cc, 10cc, 15cc). Products include Mg OSTEOCRETE (moldable/putty form) and Mg OSTEOINJECT (injectable form). Additional accessories and delivery systems are sold separately including cannulas, mixing syringes, and bead mats.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Bone Solutions develops, manufactures, and sells magnesium-based, fully resorbable bone substitute products for orthopedic surgery. Its flagship products, Mg OSTEOCRETE (high and medium viscosity moldable putty) and Mg OSTEOINJECT (low viscosity injectable), are sold as kits in 5cc, 10cc, and 15cc sizes with separate cannulas, mixing syringes, and bead mats, targeting trauma, extremity, revision, sports medicine, and spine fusion procedures performed by orthopedic surgeons in U.S. hospitals.

Product overview

Bone Solutions offers a portfolio of magnesium-based orthopedic bone substitute products built on a proprietary magnesium/potassium phosphate synthetic platform. The main products are Mg OSTEOCRETE (available in high and medium viscosity formulations for moldable and injectable applications) and Mg OSTEOINJECT (low viscosity for injectable applications). Both are fast-setting, fully synthetic bone substitutes derived from an acid/base crystallization reaction of magnesium oxide and phosphates, designed to remodel into bone through creeping substitution. The products are indicated for trauma, extremity, revision, and sports medicine procedures, with Mg OSTEOCRETE also serving intervertebral body fusions and posterolateral spine surgery.

Differentiator

Problem solved

Functional benefit

Brands

• Mg OSTEOCRETE: High viscosity and medium viscosity moldable magnesium-based bone substitute optimized for trauma, extremity, revision, sports medicine, intervertebral body fusions, and posterolateral spine surgery
• Mg OSTEOINJECT

Products and services

• Mg OSTEOCRETE Fast-setting, fully synthetic, magnesium-based bone substitute available in high and medium viscosity states. Moldable and injectable, designed for trauma, extremity, revision, sports medicine, intervertebral body fusions, and posterolateral spine surgery. Sold as kits in 5cc, 10cc, and 15cc sizes with separate cannulas, mixing syringes, and bead mats. For hospital-based orthopedic surgeons performing complex orthopedic procedures.
• Mg OSTEOINJECT Fast-setting, low viscosity, fully synthetic, pre-measured injectable magnesium-based bone substitute optimized for trauma, extremity, revision, and sports medicine applications. For hospital-based orthopedic surgeons who require injectable augmentation for anchor and tendon fixation in poor quality bone.

Quantifiable outcome

• Mg OSTEOCRETE required up to 43% greater force to completely remove bone screw compared to Ca-Cement and no treatment at 5 days (equine model)
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• BONESUPPORT AB: Swedish-listed orthobiologics company commercializing CERAMENT, an injectable bone graft substitute used in trauma and revision orthopedic indications. Closest direct competitor to Bone Solutions on chemistry philosophy (synthetic, injectable, osteoconductive bone void filler) and surgical use cases.
• Biocomposites: UK-based private manufacturer of synthetic bone graft substitutes (e.g., genex, Stimulan) used in trauma, spine, and infection management. Directly comparable as a specialized, single-platform synthetic bone substitute vendor competing against calcium phosphate incumbents.

Broad incumbents

• Stryker: One of the largest orthopedic medical device companies with a broad bone substitute and biologics portfolio (including products used in trauma and joint reconstruction). Indirectly competes with Bone Solutions across the same surgical specialties with deeper resources and established hospital contracts.
• Zimmer Biomet: Global orthopedic reconstructive and trauma leader whose Regenerative Technologies business sells bone graft substitutes and biologics into joint reconstruction and trauma — the same primary call points targeted by Bone Solutions' Mg OSTEOCRETE.
• Smith+Nephew: Orthopedics and sports medicine incumbent with a bone substitute portfolio and trauma reconstruction franchise. Notably, Bone Solutions' SVP of Sales John Fredricksen previously spent 18 years at Smith+Nephew, signaling direct competitive overlap in sales channels and surgical indications.
• Integra LifeSciences: Mid-cap medical device company with a meaningful orthopedics and tissue technologies segment offering bone graft substitutes and regenerative products. Comparable customer base (orthopedic and neurosurgical surgeons) and overlapping product positioning.
• Medtronic: Through its spine-focused businesses (now including the Divested CoreValve-era spine portfolio and legacy INFUSE bone morphogenetic protein), Medtronic is a major player in bone grafting for spinal fusion — directly relevant to Bone Solutions' stated posterolateral spine and IBF indications.
• NuVasive (now Globus Medical): Spine-focused orthopedic device company with a biologics portfolio (osteocel, AttraX) targeting spinal fusion indications. Comparable to Bone Solutions' Mg OSTEOCRETE spine use cases (intervertebral body fusion and posterolateral spine surgery).

Emerging players

• MTF Biologics: Nonprofit tissue bank supplying allograft-based bone graft substitutes (e.g., demineralized bone matrix, cancellous chips) to orthopedic and spine surgeons. Competes in the same bone void filler category but with a biological (allograft) rather than synthetic (magnesium phosphate) platform.
• Cerapedics: Private orthobiologics company commercializing i-FACTOR peptide-enhanced bone graft for cervical spine fusion and other indications. Comparable as a smaller, specialized synthetic/novel bone graft substitute vendor targeting orthopedic and spine surgical specialists.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bone-solutions-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bone Solutions